Penile Neoplasms Articles

Articles

  • Contemporary role of radiotherapy in the management of penile cancer.

    Penile cancer is a rare clinical entity that contributes to significant patient morbidity and mortality. Human papilloma virus (HPV) plays an important role in the carcinogenesis of penile squamous cell carcinoma (SCC), is associated with improved clinical outcomes, and is predictive for response to treatment with chemotherapy and radiotherapy.

    Published December 6, 2017
  • HPV-16/18 E6/E7-Specific T Lymphocytes in Patients With Relapsed HPV-Associated Cancers

    {{header-clinical-trials-navigation}}

    HPV-16/18 E6/E7-Specific T Lymphocytes in Patients With Relapsed HPV-Associated Cancers


    Condition: Human Papillomavirus-Related Carcinoma, Human Papillomavirus Positive Oropharyngeal Carcinoma, Human Papillomavirus Positive Cervical Carcinoma, Human Papillomavirus Positive Anal Carcinoma, Human Papillomavirus Positive Vulvar Carcinoma, Human Papillomavirus Positive Penile Carcinoma

    Study Type: Interventional

    Clinical Trials Identifier NCT 8-digits: NCT02379520

    Sponsor: Baylor College of Medicine

    Phase: Phase 1

    Eligibility:

    • Age: minimum 18 Years maximum N/A
    • Gender: All

    Inclusion Criteria:

    • PROCUREMENT 1. Diagnosis of a cancer for which the presence of a high risk HPV type has been documented in a biopsy sample 2. Cancer is:
    • recurrent or persistent after standard therapy
    • OR patient is unable to receive standard therapy 3. Karnofsky score ≥ 50% 4. Informed consent explained to, understood by and signed by patient/guardian. Patient/guardian given copy of informed consent TREATMENT 1. Diagnosis of a cancer for which the presence of a high risk HPV type has been documented in a biopsy sample 2. Cancer is:
    • recurrent or persistent after standard therapy
    • OR patient is unable to receive standard therapy 3. Life expectancy ≥ 6 weeks. 4. Age ≥ 18 years. 5. Karnofsky score ≥ 50% 6. Bilirubin < 3 × upper limit of normal (ULN), AST < 5 × ULN, Hgb ≥ 7.0 g/dL 7. Pulse oximetry of > 90% on room air. 8. GFR > 30 mL/min calculated by the Cockcroft-Gault, MDRD study, or CKD-EPI creatinine equations, or equivalent 9. Informed consent explained to, understood by and signed by patient/guardian. Patient/guardian given copy of informed consent 10. Sexually active patients must be willing to utilize one of the more effective birth control methods during the study and for 6 months after the study is concluded. The male partner should use a condom.

    Exclusion Criteria:

    1. PROCUREMENT
    2. Known HIV positivity. TREATMENT
    3. Currently receiving any investigational agents or have received any tumor vaccines or T cell antibodies within previous 4 weeks.
    4. Severe intercurrent infection.
    5. Pregnancy or lactation.

    View trial on ClinicalTrials.gov


    {{footer-clinical-trials-navigation}}
    Published December 22, 2017
  • Lymph node density predicts recurrence and death after inguinal lymph node dissection for penile cancer.

    To determine the impact of lymph node density (LND) on survival after inguinal lymph node dissection (ILND) for penile cancer.

    Our institutional penile cancer database was queried for patients who underwent ILND.

    Published January 26, 2017
  • Non-Comparative, Open-Label, Multiple Cohort, Phase 1/2 Study of Nivolumab Monotherapy and Nivolumab Combination Therapy in Subjects With Virus-Positive and Virus-Negative Solid Tumors

    {{header-clinical-trials-navigation}}

    Non-Comparative, Open-Label, Multiple Cohort, Phase 1/2 Study of Nivolumab Monotherapy and Nivolumab Combination Therapy in Subjects With Virus-Positive and Virus-Negative Solid Tumors


    Condition: Various Advanced Cancer

    Study Type: Interventional

    Clinical Trials Identifier NCT 8-digits: NCT02488759

    Sponsor: Bristol-Myers Squibb

    Phase: Phase 1/Phase 2

    Eligibility:

    • Age: minimum 18 Years maximum N/A
    • Gender: All

    Inclusion Criteria:

    • Histopathologic confirmation of the following tumor types (please refer to protocol for full details pertaining to eligible tumor types): 1. Merkel Cell Carcinoma 2. Gastric or Gastro-Esophageal junction carcinoma (No longer enrolling this tumor type) 3. Nasopharyngeal Carcinoma 4. Squamous cell carcinoma (SCC) of the cervix, vagina, or vulva 5. Squamous cell carcinoma of the Head and Neck 6. Squamous cell carcinoma of the anal canal and penis 7. Recurrent/metastatic SCC of the cervix not amenable to curative treatment with surgery and/or radiation therapy who are unsuitable for platinum-based therapy may enroll in the cervical cancer Combination B expansion cohort
    • Measurable disease by CT or MRI
    • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
    • Patient willing to comply to provide tumor tissue (archival or fresh biopsy specimen)
    • Men and women of age 18 or older

    Exclusion Criteria:

    • Active brain metastases or leptomeningeal metastases
    • Patients with active, known or suspected autoimmune disease
    • Patients with a condition requiring systemic treatment with either corticosteroids or other immunosuppressive medications
    • Patients with hepatitis
    • Patients with HIV
    • Pregnant or breastfeeding women

    View trial on ClinicalTrials.gov


    {{footer-clinical-trials-navigation}}
    Published December 22, 2017